What is ARVN stock price today?

ARVN (Arvinas Inc) stock is trading at $8.98 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is ARVN stock going up or down today?

ARVN stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy ARVN stock now?

The decision to buy ARVN depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is ARVN a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for ARVN based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is ARVN stock overvalued or undervalued?

Use our DCF valuation calculator to determine if ARVN is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is ARVN's P/E ratio?

P/E ratio data for ARVN will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is ARVN's market cap?

ARVN (Arvinas Inc) has a market capitalization of $0.58 billion, making it a small-cap stock.

What is ARVN's price to book ratio?

ARVN trades at a price-to-book (P/B) ratio of 1.50, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does ARVN pay dividends?

ARVN does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is ARVN's dividend yield?

ARVN does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is ARVN stock a good long-term investment?

ARVN's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is ARVN's revenue growth rate?

ARVN has shown revenue growth of -0.9% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

ARVN is currently operating at a loss. Some companies prioritize growth over profitability in early stages. Review our financial analysis for detailed insights.

What are the risks of investing in ARVN?

Key risks for ARVN include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does ARVN compare to its competitors?

Compare ARVN to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize ARVN's performance and positioning.

What is ARVN's stock price target for 2026?

Our AI model provides price targets for ARVN based on fundamental analysis: Bull case $11.67 (+30%), Base case $10.33 (+15%), Bear case $8.08 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about ARVN?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for ARVN. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is ARVN's next earnings report?

ARVN reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

ARVN - Arvinas Inc

NYSE * Health Care * Biotechnology

$8.98

+$0.14 (+1.58%)

About Arvinas Inc

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

ARVN Key Statistics

Market Cap

$579.40M

P/B Ratio

1.50

EPS

$-3.18

Revenue Growth

-0.9%

Profit Margin

-2.5%

Employees

246

How ARVN Compares to Peers

ARVN is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
ARVN(This stock)	$579.40M	N/A	-1%	-2.5%	-
AMGNAmgen Inc	$181.77B	23.4	0%	0.2%	vs AMGN
GILDGilead Sciences	$166.90B	18.3	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$113.59B	26.5	0%	0.4%	vs VRTX
REGNRegeneron Pharmaceuticals	$64.45B	15.0	0%	0.3%	vs REGN
BIIBBiogen Inc	$28.94B	21.1	0%	0.1%	vs BIIB

Arvinas Inc Company Information

Headquarters: Connecticut; U.S.A
Website: www.arvinas.com
Sector: Health Care
Industry: Biotechnology

ARVN - Arvinas Inc

About Arvinas Inc

ARVN Key Statistics

How ARVN Compares to Peers

Arvinas Inc Company Information

ARVN Lician Score

ARVN Financial Snowflake

Upcoming Events for ARVN